These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Exanthematic diseases during pregnancy and attention-deficit/hyperactivity disorder (ADHD). Arpino C; Marzio M; D'Argenzio L; Longo B; Curatolo P Eur J Paediatr Neurol; 2005; 9(5):363-5. PubMed ID: 16061411 [TBL] [Abstract][Full Text] [Related]
46. [Relation between serologic verification and anamnestic data on the principal virus diseases of infancy]. Profeta ML; Ferrante P; Mendogni D Boll Ist Sieroter Milan; 1987; 66(5):367-76. PubMed ID: 3449098 [TBL] [Abstract][Full Text] [Related]
47. Measles, mumps, rubella, and human parvovirus B19 infections and neurologic disease. Bale JF Handb Clin Neurol; 2014; 121():1345-53. PubMed ID: 24365423 [TBL] [Abstract][Full Text] [Related]
48. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy. Sultana R; Rahman MM; Hassan Z; Hassan MS Scand J Immunol; 2006 Dec; 64(6):684-9. PubMed ID: 17083626 [TBL] [Abstract][Full Text] [Related]
49. Guillain-Barre syndrome following specific viral infections--an appraisal. Murthy JM J Assoc Physicians India; 1994 Jan; 42(1):27-9. PubMed ID: 7836243 [TBL] [Abstract][Full Text] [Related]
50. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years. Vesikari T; Baer M; Willems P Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879 [TBL] [Abstract][Full Text] [Related]
51. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age. Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882 [TBL] [Abstract][Full Text] [Related]
52. SMALL INTESTINAL MUCOSA IN CERTAIN VIRAL DISEASES. SHEEHY TW; ARTENSTEIN MS; GREEN RW JAMA; 1964 Dec; 190():1023-8. PubMed ID: 14212284 [No Abstract] [Full Text] [Related]
53. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine. Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835 [TBL] [Abstract][Full Text] [Related]
54. Measles, mumps and rubella infections and atopic disorders in MMR-unvaccinated and MMR-vaccinated children. Bernsen RM; van der Wouden JC Pediatr Allergy Immunol; 2008 Sep; 19(6):544-51. PubMed ID: 18266826 [TBL] [Abstract][Full Text] [Related]
56. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax. Reisinger KS; Brown ML; Xu J; Sullivan BJ; Marshall GS; Nauert B; Matson DO; Silas PE; Schödel F; Gress JO; Kuter BJ; Pediatrics; 2006 Feb; 117(2):265-72. PubMed ID: 16452343 [TBL] [Abstract][Full Text] [Related]
57. Severe complications of varicella in previously healthy children in Germany: a 1-year survey. Ziebold C; von Kries R; Lang R; Weigl J; Schmitt HJ Pediatrics; 2001 Nov; 108(5):E79. PubMed ID: 11694663 [TBL] [Abstract][Full Text] [Related]
58. Viral Infections and diseases of the heart. Lansdown AB Prog Med Virol; 1978; 24():70-113. PubMed ID: 360296 [No Abstract] [Full Text] [Related]
59. [Study of chromosome aberrations during human viral diseases]. Brusquet Y; Stahl A C R Seances Soc Biol Fil; 1968; 162(2):480-5. PubMed ID: 4303206 [No Abstract] [Full Text] [Related]
60. Malnutrition and the common communicable diseases of childhood in rural Guatemala. Salomon JB; Mata LJ; Gordon JE Am J Public Health Nations Health; 1968 Mar; 58(3):505-16. PubMed ID: 5689218 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]